60.48
price down icon2.04%   -1.26
after-market Dopo l'orario di chiusura: 60.48
loading
Precedente Chiudi:
$61.74
Aprire:
$62.2
Volume 24 ore:
525.81K
Relative Volume:
0.87
Capitalizzazione di mercato:
$3.80B
Reddito:
$112.53M
Utile/perdita netta:
$-258.91M
Rapporto P/E:
-13.97
EPS:
-4.33
Flusso di cassa netto:
$-124.42M
1 W Prestazione:
+0.57%
1M Prestazione:
+16.22%
6M Prestazione:
+20.50%
1 anno Prestazione:
+59.12%
Intervallo 1D:
Value
$60.31
$62.85
Intervallo di 1 settimana:
Value
$59.54
$62.85
Portata 52W:
Value
$35.17
$68.58

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
Nome
Rhythm Pharmaceuticals Inc
Name
Telefono
857-264-4280
Name
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Name
Dipendente
283
Name
Cinguettio
@rhythmpharma
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
RYTM's Discussions on Twitter

Confronta RYTM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
60.48 3.80B 112.53M -258.91M -124.42M -4.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-07 Aggiornamento BofA Securities Neutral → Buy
2025-03-05 Ripresa Stifel Buy
2025-01-02 Iniziato Jefferies Buy
2024-12-20 Iniziato Oppenheimer Outperform
2024-10-21 Iniziato Guggenheim Buy
2024-09-18 Iniziato H.C. Wainwright Buy
2024-09-17 Iniziato JMP Securities Mkt Outperform
2024-05-08 Downgrade BofA Securities Buy → Neutral
2023-12-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2023-08-01 Aggiornamento BofA Securities Neutral → Buy
2023-01-18 Ripresa Canaccord Genuity Buy
2022-08-08 Aggiornamento Goldman Neutral → Buy
2022-08-05 Aggiornamento BofA Securities Underperform → Neutral
2022-06-17 Reiterato Needham Buy
2022-03-02 Ripresa Stifel Buy
2022-02-17 Aggiornamento Ladenburg Thalmann Neutral → Buy
2021-12-08 Iniziato Wells Fargo Overweight
2021-11-19 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-14 Ripresa Goldman Neutral
2021-08-04 Downgrade BofA Securities Neutral → Underperform
2021-08-04 Downgrade Ladenburg Thalmann Buy → Neutral
2020-11-30 Downgrade BofA Securities Buy → Neutral
2020-01-08 Iniziato Goldman Sell
2019-07-12 Aggiornamento Stifel Hold → Buy
2019-07-08 Iniziato Canaccord Genuity Buy
2019-03-13 Iniziato Ladenburg Thalmann Buy
2018-09-07 Ripresa Morgan Stanley Overweight
2018-06-25 Reiterato Needham Buy
2018-06-15 Reiterato Needham Buy
2017-10-30 Iniziato BofA/Merrill Buy
2017-10-30 Iniziato Needham Buy
Mostra tutto

Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie

pulisher
Apr 15, 2025

Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - markets.businessinsider.com

Apr 15, 2025
pulisher
Apr 13, 2025

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - MSN

Apr 13, 2025
pulisher
Apr 12, 2025

Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded at Bank of America - MarketBeat

Apr 12, 2025
pulisher
Apr 11, 2025

Canaccord maintains Buy on Rhythm Pharma following Ph3 data By Investing.com - Investing.com Canada

Apr 11, 2025
pulisher
Apr 11, 2025

Rhythm Pharmaceuticals (RYTM) Target Price Raised by BofA Amid P - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Rhythm Pharmaceuticals Stock (RYTM) Erases YTD Losses This Week - AskTraders.com

Apr 10, 2025
pulisher
Apr 09, 2025

Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 08, 2025

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (NASDAQ:RYTM) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Rhythm’s setmelanotide cuts BMI by 20% - The Pharma Letter

Apr 08, 2025
pulisher
Apr 08, 2025

Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView

Apr 08, 2025
pulisher
Apr 08, 2025

Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Rhythm Pharmaceuticals shares rise on raised target to $80 By Investing.com - Investing.com UK

Apr 08, 2025
pulisher
Apr 08, 2025

Canaccord raises Rhythm Pharma stock target to $92, maintains buy By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

Positive Phase 3 Results and Market Potential Boost Rhythm Pharmaceuticals’ Price Target - TipRanks

Apr 08, 2025
pulisher
Apr 07, 2025

BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals (RYTM) Surges as Obesity Drug Achieves Ke - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Anticipates Smooth Sailing For Setmelanotide After Phase III Success - insights.citeline.com

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals’ Bold Moves: What’s Next? - timothysykes.com

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals price target raised to $77 from $72 at Morgan Stanley - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm posts late-stage trial win for lead asset against rare form of obesity - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

BofA lifts Rhythm Pharmaceuticals stock rating to Buy, target to $63 By Investing.com - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals (RYTM) Achieves Success in Phase 3 Obesit - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Plans Regulatory Filings After Positive I - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Why Rhythm Pharmaceuticals Stock is Climbing High - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder - Yahoo

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals’ Unexpected Surge: A Stock to Watch? - timothysykes.com

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharma's drug for rare obesity meets late-stage trial goal - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals (RYTM) Reports Promising Phase 3 Trial Re - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals (RYTM) Achieves Phase 3 Trial Success wit - GuruFocus

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals stock rises on trial success By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals stock rises on trial success - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in trial - MSN

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals' Obesity Treatment Meets Main Goal in Phase 3 Study, Shares Rise - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Announces Positive Phase 3 Trial Results - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals says Phase 3 TRANSCEND trial meets primary endpoint - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharma Reports Positive Topline Results From Phase 3 TRANSCEND Trial With Setmelanotide - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - GlobeNewswire

Apr 07, 2025

Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Capitalizzazione:     |  Volume (24 ore):